Lilly's first 10-K reveals 58% revenue surge driven by GLP-1s, but faces supply, pricing risks

This is the first disclosure of Lilly's business description in this filing. The company operates in a single segment focused on human pharmaceutical products, with a portfolio spanning cardiometabolic health, oncology, immunology, and neuroscience. Key products include Mounjaro/Zepbound, Jardiance, Trulicity, Verzenio, Taltz, and newly launched Kisunla.

Lilly explicitly discloses that anti-obesity medicines (Mounjaro/Zepbound) face significant reimbursement barriers in the U.S. and internationally, with many commercial plans excluding coverage and Medicare not covering weight loss indications. Given that these products represent a significant revenue portion, access restrictions pose material business risk.

Lilly identifies a new competitive threat from counterfeit and compounded versions of incretin medicines (GLP-1 drugs like Mounjaro/Zepbound). This could divert sales, erode pricing, create safety concerns, and damage brand reputation. The company explicitly states this could materially impact business.

Lilly discloses that demand for its incretin products (Mounjaro/Zepbound) exceeded manufacturing capacity during 2024. This indicates supply constraints that could limit revenue growth for these high-value products and represents a material operational challenge given their significance to overall revenue.

Lilly discloses material dependence on China-based suppliers and identifies specific risks from the proposed BIOSECURE Act and February 2025 tariffs. The company explicitly states that disruption from legislation or trade restrictions could significantly impact business and results, representing a new and material supply chain risk disclosure.

Lilly discloses its restricted distribution approach to the 340B drug pricing program and notes this is subject to ongoing litigation that could materially impact business. The company also discloses November 2024 litigation against HRSA over a proposed cash replenishment model, indicating active regulatory conflict over pricing and distribution.

Lilly identifies proposed EU pharmaceutical legislation that could have negative market impact if enacted as drafted. This represents regulatory uncertainty in a major market, though implementation timing remains unknown.

First disclosure of patent protection timelines for key products. Mounjaro/Zepbound has compound patent protection through 2036-2040 in major markets, but U.S. data protection expires in 2027, potentially allowing biosimilar entry earlier than patent expiry. This provides investors with critical exclusivity timelines for the company's highest-growth products.

Lilly discloses launch of a new direct-to-consumer platform that bypasses traditional distribution channels for obesity, migraine, and diabetes medicines. This represents a strategic shift in go-to-market approach but also introduces new operational and regulatory risks as acknowledged in the filing.

Lilly discloses major capital investments in manufacturing capacity across six sites globally to support demand for current and pipeline products. This indicates significant capital deployment to address supply constraints and support growth, particularly for incretin medicines.

This is the first 10-K filing for LLY in the dataset, so the entire MD&A section is new. There is no baseline filing to compare against, meaning all content represents newly disclosed information rather than changes from a prior period.

LLY reported 2024 revenue of $45.0 billion, up 32% from 2023's $34.1 billion and 58% from 2022's $28.5 billion. Net income reached $10.6 billion in 2024, more than doubling from $5.2 billion in 2023. This represents substantial growth driven primarily by cardiometabolic products.

Mounjaro generated $11.5 billion in 2024 revenue (up from $5.2 billion in 2023), while Zepbound contributed $4.9 billion in its first full year. These GLP-1 products are now LLY's largest revenue drivers, representing approximately 36% of total 2024 revenue combined.

LLY disclosed $11.5 billion in sales rebates and discounts accruals as of December 31, 2024, relatively flat from $11.7 billion in 2023. The auditor identified Medicaid, Managed Care, and Medicare rebate accruals as a critical audit matter due to estimation complexity and subjectivity.

Long-term debt increased 56% to $28.5 billion at year-end 2024 from $18.3 billion in 2023. Cash flow statement shows $11.4 billion in new long-term debt proceeds during 2024, likely to fund capacity expansion and R&D investments supporting the GLP-1 franchise.

Net property and equipment grew 32% to $17.1 billion from $12.9 billion, with capital expenditures of $5.1 billion in 2024 (up from $3.4 billion in 2023). This reflects significant manufacturing capacity investments to meet demand for incretin medicines.

LLY expensed $3.3 billion for acquired in-process R&D in 2024, down from $3.8 billion in 2023 but up significantly from $908.5 million in 2022. This reflects ongoing business development activity to supplement the internal pipeline, though at a moderating pace.

New product liability litigation emerged in 2023 regarding incretin medicines, with cases consolidated in federal MDL in Pennsylvania. Plaintiffs filed a master complaint in November 2024. This represents emerging litigation risk for LLY's highest-revenue product category.

LLY disclosed ongoing investigations by multiple state attorneys general and federal agencies regarding insulin and diabetes medication pricing. The company is cooperating with these inquiries, which could result in future settlements or regulatory actions.

A jury verdict went against LLY in August 2022 regarding average manufacturer price calculations for Medicaid. LLY has appealed to the Seventh Circuit, and the outcome remains uncertain. This could have implications for Medicaid reimbursement calculations.

LLY settled a breach of contract dispute with RCT in July 2024 related to manufacturing processes for Humalog and Humulin. The settlement involves conditional payments based on appeal outcomes, with LLY stating remaining amounts should not be material.

The company discloses the inherent high failure rate in drug development and the risk that new products may not generate sufficient returns to replace revenues from products losing patent protection. This is a fundamental business risk for pharmaceutical companies, highlighting the uncertainty in recouping substantial R&D investments.

The company faces intensifying government and private payer controls on drug pricing, particularly for diabetes, obesity, and Alzheimer's products. The IRA's Medicare price negotiation program selected Jardiance in 2023 with a 66% discount effective 2026, and additional products are expected to be selected in future years, which could significantly accelerate revenue erosion.

The company has significant revenue concentration in a small number of products, with six products representing 75% of total revenues and three incretin medicines alone accounting for 48%. This concentration creates substantial risk if any of these products face safety issues, competitive pressure, or loss of patent protection.

The company specifically identifies Trulicity, a major revenue contributor, as facing imminent loss of patent protection. Given that loss of exclusivity typically results in rapid and severe revenue declines, especially in the U.S., this represents a material near-term revenue risk.

The company experienced supply constraints for its high-growth incretin medicines in 2024. While current supply exceeds U.S. demand, the dynamic nature of demand and long lead times for manufacturing expansion create risk of future supply-demand mismatches that could limit revenue growth or result in excess capacity.

The company faces growing challenges from counterfeit and illegally compounded versions of its incretin products. These unauthorized products pose patient safety risks and could damage the company's reputation and business, with potentially costly enforcement efforts that may prove ineffective.

The company has material dependencies on China-based suppliers for critical supply chain components. U.S. legislative proposals like the BIOSECURE Act and new tariffs imposed in February 2025 could disrupt these supply chains, with limited alternative sourcing options available, potentially causing significant delays and costs.

The company is deploying AI across operations but faces risks including deficient AI-generated content, competitive disadvantages if competitors adopt AI more effectively, technical challenges with accuracy and reliability, regulatory uncertainty, and potential data security or intellectual property issues. New regulations like the EU AI Act may impose compliance burdens.

Recent escalation of trade tensions with new tariffs on Chinese goods and threatened tariffs on other major trading partners creates uncertainty for the company's international operations, supply chains, and clinical trials. These developments could increase costs, disrupt operations, and complicate business activities across multiple geographies.